Integrating knowledge graphs into machine learning models for survival prediction and biomarker discovery in patients with non–small-cell lung cancer

Accurate survival prediction for Non-Small Cell Lung Cancer (NSCLC) patients remains a significant challenge for the scientific and clinical community despite decades of advanced analytics. Addressing this challenge not only helps inform the critical aspects of clinical study design and biomarker discovery but also ensures that the 'right patient' receives the 'right treatment'. However, survival prediction is a highly complex task, given the large number of 'omics; and clinical features, as well as the high degree of freedom that drive patient survival. Prior knowledge could play a critical role in uncovering the complexity of a disease and understanding the driving factors affecting a patient's survival. We introduce a methodology for incorporating prior knowledge into machine learning-based models for prediction of patient survival through Knowledge Graphs, demonstrating the advantage of such an approach for NSCLC patients. Using data from patients treated with immuno-oncologic therapies in the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials, we found that the use of knowledge graphs yielded significantly improved hazard ratios, including in the POPLAR cohort, for models based on biomarker tumor mutation burden compared with those based on knowledge graphs. Use of a model-defined mutational 10-gene signature led to significant overall survival differentiation for both trials. We provide parameterized code for incorporating knowledge graphs into survival analyses for use by the wider scientific community.

Authors

Institutions

Publication Details

Journal
Journal of Translational Medicine
Published
2024-08-05
DOI
https://doi.org/10.1186/s12967-024-05509-9
Citations
13
Primary Topic
Bioinformatics and Genomic Networks
Type
article
Field-Weighted Citation Impact
3.04

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Integrating knowledge graphs into machine learning models for survival prediction and biomarker discovery in patients with non–small-cell lung cancer

Gustavo Alonso Arango Argoty, Ioannis Kagiampakis, Natasha Markuzon, Krishna C. Bulusu et al.
13 citations
Journal of Translational Medicine
Bioinformatics and Genomic Networks
3.04
article

Integrating knowledge graphs into machine learning models for survival prediction and biomarker discovery in patients with non–small-cell lung cancer

Gustavo Alonso Arango Argoty, Ioannis Kagiampakis, Natasha Markuzon, Krishna C. Bulusu, Etai Jacob, Chao Fang, Mohammad Hassan Khalid
article en
13 citations

Abstract

Accurate survival prediction for Non-Small Cell Lung Cancer (NSCLC) patients remains a significant challenge for the scientific and clinical community despite decades of advanced analytics. Addressing this challenge not only helps inform the critical aspects of clinical study design and biomarker discovery but also ensures that the 'right patient' receives the 'right treatment'. However, survival prediction is a highly complex task, given the large number of 'omics; and clinical features, as well as the high degree of freedom that drive patient survival. Prior knowledge could play a critical role in uncovering the complexity of a disease and understanding the driving factors affecting a patient's survival. We introduce a methodology for incorporating prior knowledge into machine learning-based models for prediction of patient survival through Knowledge Graphs, demonstrating the advantage of such an approach for NSCLC patients. Using data from patients treated with immuno-oncologic therapies in the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials, we found that the use of knowledge graphs yielded significantly improved hazard ratios, including in the POPLAR cohort, for models based on biomarker tumor mutation burden compared with those based on knowledge graphs. Use of a model-defined mutational 10-gene signature led to significant overall survival differentiation for both trials. We provide parameterized code for incorporating knowledge graphs into survival analyses for use by the wider scientific community.

Journal of Translational MedicineVol. 22(1)
AstraZeneca (United Kingdom) (GB), AstraZeneca (Singapore) (SG), AstraZeneca (Brazil) (BR), AstraZeneca (United States) (US)
AstraZeneca
Openalex Percentile: Top 8%
Bioinformatics and Genomic Networks
3.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.